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Introduction
Epstein-Barr virus (EBV), the causative agent of heterophilepositive acute infectious mononucleosis, is a successful pathogen in the human species, asymptomatically infecting most normal adult individuals. Sites of persistent infection include the oropharynx, where EBV is periodically shed, and the peripheral blood, where EBV latently infects a proportion of the B cells (for a review see reference 1). When cultured in vitro, these B cells spontaneously give rise to long-term EBV-infected B cell lines (2) .
In spite oftheir potential for unlimited growth, B cells naturally infected with EBV only rarely give rise to lymphoproliferative disease in man. Credit for such successful restraint is attributable, primarily, to T cell immunity (for reviews see refer-ences 3, 4). Through killing and other suppressor functions, T cells from EBV-seropositive individuals regulate the growth of EBV-infected B cells. Severe T cell immunodeficiency, such as that occurring in AIDS and solid organ transplant recipients, can result in the uncontrolled expansion of B lymphocytes naturally infected with EBV and the development oflymphoproliferative disease (for reviews see references 5, 6) . As many as 32% of solid organ transplant recipients may develop lymphoproliferative disease generally involving EBV-infected B cells (6) .
IL-6, a multifunctional cytokine produced by monocytes, fibroblasts, endothelial cells, and other cell types (for a review see reference 7) promotes growth of EBV-infected B cells, acting as an autocrine and/or paracrine growth factor (8, 9) . In addition, this cytokine has been shown to increase the tumorigenicity of EBV-immortalized B cells in athymic mice (10, 11) .
In the present study we examined the possibility that IL-6 may play a role in the development of EBV-positive lymphoproliferative disease in immunosuppressed solid organ transplant recipients. To this end, we have measured IL-6 bioactivity in serum/plasma samples of solid organ transplant recipients who developed lymphoproliferative disease or who had uncomplicated courses posttransplant. We also investigated IL-6 production in vitro by the lymphoproliferative lesions.
Methods
Studypopulation. The study population consisted of 32 patients undergoing solid organ transplantation at the University of Pittsburgh, 20 normal controls, 9 patients with heterophile-positive acute infectious mononucleosis, and 2 patients with AIDS. Relevant clinical data on the transplant patients are shown in Tables I and II. EBV serology was performed by immunofluorescence, as described ( 12) . Patients were diagnosed as having a primary EBV infection by the presence of IgM anti-viral capsid antigen (VCA)' antibodies or the de novo development of IgG anti-VCA antibodies. Patients were diagnosed as having EBV reactivation or reinfection by the presence of a fourfold or higher rise in IgG anti-VCA or anti-early antigen (EA) antibodies ( 13) . The diagnosis of posttransplant lymphoproliferative disease (PTLD, 14) was made when tissue biopsy or autopsy (a) was histologically consistent with a lymphoproliferative process and (b) contained EBV as demonstrated by the detection of EBV nuclear antigens by anti-complement immunofluorescence ( 15) or of EBV-DNA by Southern blot hybridization with an EcoRI fragment of EBV ( 16, 17) .
Cell cultures. Tissue fragments obtained as biopsy or autopsy specimens were reduced to single cell suspensions by first separating into small fragments and then treating with I mg/ml Collagenase-Dispase (Boehringer Mannheim, Indianapolis, IN) in PBS at 37°C for 1-2 h with rotation. After washing, the cells were suspended at 2-5 X 106 cells/ml in tissue culture medium consisting of RPMI 1640 medium 103.1 (9) * Number of days after transplantation condition was apparent. P = primary infection and R/R = reactivation or reinfection, as determined by serology.
1Period in days during which samples were obtained.
Maximum level of IL-6 (U/ml) in samples (day after transplantation sample was obtained).
(Gibco, Grand Island, NY) supplemented with 10% heat inactivated fetal calf serum, 2 mM L-glutamine, 12.5 U/ml penicillin, 12.5 Ag/ml streptomycin, 0.5 gg/ml amphotericin B (all reagents from Gibco), and 0.5,gg/ml Cyclosporin A (Sandoz Pharmaceutical Co., East Hanover, NJ) in T25 tissue culture flasks (Costar, Cambridge, MA). Cultures were fed once or twice per week and split when appropriate. Mononuclear cells, obtained by standard techniques from the peripheral blood of patients with acute infectious mononucleosis (18) , were cultured at 1 X 106 cells/ml in T25 tissue culture flasks containing 5 ml tissue culture medium. Spontaneous outgrowth of EBV-immortalized cells was assessed by microscopy, as described (19).
AssaysforIL-6. The murine hybridoma cell line B9 (a gift ofDr. R.
Nordan, National Institutes ofHealth) was used in a standard assay for IL-6 bioactivity (20) . 1 U of IL-6 bioactivity in this assay is defined as the activity inducing /2 maximal proliferation of B9 cells. An IL-6 concentration of I U/ml corresponds to -10 pg/ml ofE. coli-derived IL-6 used throughout as a laboratory standard (Sandoz Pharmaceutical Co.) and to 5.5 U/ml of the NIH interim standard (preparation 88/ 414). Serum/plasma samples were heat-inactivated at 56°C for 30 min prior to testing for IL-6 bioactivity. Neutralization experiments were performed as previously described (8 
Results
Abnormally high serum/plasma IL-6 bioactivity in transplant recipients with lymphoproliferative disease. IL-6 bioactivity was measured by the B9 cell growth assay in 220 coded serum/ plasma samples from 31 solid organ transplant recipients (Tables I and II), and compared to that in 20 serum/plasma samples from 20 normal individuals. Organs transplanted included liver (17 patients), kidney ( 10 patients), heart (2 patients), lung (1 patient), and heart plus lung ( 1 patient). 10 of the 31 solid organ recipients had uncomplicated courses posttransplant, 2 patients were diagnosed with organ rejection, and 1 with Gram negative sepsis ( Table I ). The remaining 18 patients (Table II) had posttransplant courses complicated with PTLD (posttransplant lymphoproliferative disease) defined by tissue histology and the presence of EBV-DNA or nuclear antigens (5) .
The mean (±SD) IL-6 bioactivity content in 20 normal serum/plasma samples was 11.4 (6.4) U/ml (normal range 2 7.1 < 15.6 with 99% confidence interval). Most ofthe serum/ plasma samples (157/220, 71.4%) from solid organ transplant recipients had a normal IL-6 bioactivity content. The remaining 64 samples had an abnormally high (> 15.6 U/ml) IL-6 bioactivity content, 50 of which (78.1%) derived from transplant recipients who developed PTLD, 2 from a septic patient, 2 from 2 patients with organ rejection, and 10 from 3 transplant recipients with uncomplicated courses posttransplant.
Levels of IL-6 bioactivity over time in serum/plasma samples of each of 10 organ transplant recipients with uncomplicated clinical courses post-transplant are depicted in Fig. 1 . As shown, seven ofthese patients had normal IL-6 bioactivity levels throughout. The remaining three patients (W.K., P.S., and F.S.) had serum/plasma samples with IL-6 bioactivity levels two-to threefold above normal, with a mean maximum IL-6 6 (97) 6 (210) 14 (170) 9 (1769) 14 (249) 12 (293) 10 (41) 5 (116) 10 (300) 12 ( The results are expressed as U/ml.
bioactivity 5-to 100-fold above normal. These abnormal spikes of serum/plasma IL-6 bioactivity temporally preceded the diagnosis ofPTLD in I1 of 17 cases, and in one case accompanied and in five cases followed the diagnosis ofPTLD. Three of these latter five patients had an early diagnosis of PTLD either because of disease location in the brain (J.Y.) or obstructing the biliary track (E.F.), or because PTLD was a coincidental microscopic finding in a rejected organ (M.B.).
Abnormal elevations of serum/plasma IL-6 bioactivity were also observed in three solid organ transplant recipients who developed either organ rejection (H.S. and K.R.) or sepsis (L.P.) (Fig. 3) . In all cases, peak serum/plasma IL-6 bioactivity temporally coincided with the clinical diagnosis of organ rejection and sepsis.
There was no correlation between abnormal serum/plasma IL-6 bioactivity in posttransplant recipients and change in EBV status, as determined by serology (Tables I and II) . Among the 23 patients with abnormally high serum/plasma IL-6 levels, eight underwent a primary EBV infection at the time of, or shortly after transplant, five had serologic evidence of EBV reactivation or reinfection, and 10 had no serologic evidence of a change in EBV status. Together, these results demonstrated that abnormally high levels ofIL-6 bioactivity in serum ofposttransplant recipients generally precede or accompany serious complications such as PTLD, organ rejection, or sepsis.
IL-6 production by PTLD tissue in vitro. The occurrence of abnormally high serum plasma IL-6 bioactivity in patients who developed PTLD prompted us to examine whether the lymphoproliferative tissue was a source of IL-6. To this end, biopsy or autopsy-derived tissue specimens from 10 of the 18 posttransplant recipients diagnosed with PTLD were single-cell suspended, cultured in vitro for 20 to 235 d, and tested for IL-6 secretion in culture over time. For nine of these specimens the earliest conditioned culture medium after PTLD tissue transfer to culture was available for IL-6 testing. As shown (Table III) , each of the early culture supernatants contained IL-6 bioactivity in spite ofthe fact that the tissue specimens were often very small. It should be noted that these early PTLD conditioned culture media contained 43 to 247,273 IL-6 U/ml. The remaining two PTLD tissues (J.R. and S.S.), for which no early conditioned media were available for testing, were found to be the two highest IL-6 producers when first tested after 44 (1.9 X 106 IL-6 U/ml) and 126 (1.25 X 106 U/ml) days of culture, respectively. Overall, the mean maximum level of IL-6 secreted in the culture supernatant by PTLD tissues was 35,025 U/ml.
Cell cultures of PTLD tissue continued to produce IL-6 at levels comparable to those produced immediately after initiation ofculture for at least 20 d. In two cases (J.R. and S.S.) high level IL-6 production in culture continued for 108 and 126 d, respectively.
In contrast to the results with PTLD tissues, the IL-6 bioactivity content in early culture supernatants of peripheral blood mononuclear cells from 9 patients with acute infectious mononucleosis was less than 10 U/ml (Table IV) . Similarly low (< 10 U/ml) was the IL-6 bioactivity content in three early culture supernatants of single cell suspended lymphoid tissue biopsied for suspected lymphoproliferative disease but found to be negative (Table IV) . One of these (G.P.) derived from a solid organ transplant recipient, two from HIV-positive individuals. In vitro IL-6 production continued to be low in peripheral blood mononuclear cell cultures from patients with acute infectious mononucleosis undergoing spontaneous outgrowth in vitro and from the inflammatory lymph nodes. Representative patterns of IL-6 production over time by PTLD tissue and infectious mononucleosis-derived mononuclear cells are shown in Fig. 4 .
The presence ofIL-6 in culture supernatants ofeach PTLD tissue studied was confirmed by a specific ELISA (data not shown).
In vitro cultures of PTLD tissues were generally composed of suspension cells, (Fig. 5) , cultures of unseparated cells from PTLD tissues containing adherent cells together with suspension cells produced large quantities of IL-6 bioactivity, but cultures containing suspension cells alone generally produced little IL-6. In contrast to the suspension cells, cultures containing adherent cells alone produced large quantities of IL-6 bioactivity. The differences in IL-6 levels detected in supernatants of cultures with and without adherent cells could not be attributed to differences in cell densities. The adherent cells, producing high levels of IL-6, were nonproliferating, and were estimated to reach maximum densities of 1 X 105 cells/ ml. The suspension cells, producing low levels of IL-6, were actively proliferating, and reached cell densities of 0.3-1.0 X 106 cells/ml. It should be noted that, after transfer to culture vessels devoid of adherent cells, the PTLD-derived B cells continued to grow at a similar rate (not shown). These findings demonstrate that the PTLD-derived adherent cells, but not the suspension B cells, are capable of high level IL-6 production, and suggest that the adherent cells are the principal source of IL-6 production.
Discussion
In the present study, we have explored a potential role for IL-6 in the development oflymphoproliferative disease in immunocompromised solid organ transplant recipients. Levels ofcirculating IL-6 bioactivity were found to be abnormally elevated, albeit transiently, in 17 of 18 transplant recipients who developed PTLD with a mean maximal serum/plasma concentration of 196.7 U/ml. This represents an increase of 16.4-fold above the mean level in normal individuals ( 11.3 U/ml). In contrast, only 3 of 10 patients with relatively uncomplicated * IL-6 content (U/ml) in initial culture supernatant after transfer to in vitro culture (day of culture in which the supernatant was obtained). * Total number of days in culture during which IL-6 testing was performed. § Highest IL-6 content (U/ml) in culture supernatants (day of culture in which the supernatant was obtained). 11 Not done, initial culture supernatant not available for testing. The first culture supernatant from PTLD specimen JR was obtained on day 44 of culture and contained 1.9 X 106 IL-6/U ml; the first culture supernatant from PTLD specimen SS was obtained on day 126 of culture and contained 1.25 x 106 IL-6 U/ml. courses posttransplant were found to have abnormally high IL-6 bioactivity levels in the circulation, with a mean maximal concentration of 41.4 U/ml. When transferred to culture in vitro, each of 11 lymphoproliferative lesions from 10 transplant recipients secreted large amounts of IL-6 without stimulation with exogenously added mitogens and cytokines. On the average, the IL-6 content in culture supernatants reached levels of 35,025 U/ml. In all cases, the presence of IL-6 was detected in the initial culture supernatant after transfer of the lymphoproliferative lesions to culture and conditioning for 1-14 d. In contrast, inflammatory lymphoid tissue negative for lymphoproliferative disease secreted low levels of IL-6 when cultured in vitro under identical conditions. Together, these findings suggest that IL-6 secretion is an intrinsic property ofPTLD tissues rather than the result of in vitro stimulation.
It is likely that the lymphoproliferative lesions represent a source of the abnormally high IL-6 bioactivity detected in the patients' circulation. However, high levels of IL-6 secreted by PTLD tissues in vitro generally continued over several weeks while abnormal elevations ofIL-6 bioactivity in the circulation of PTLD patients were transient in many cases. If the lymphoproliferative lesions were the principal source of IL-6 in the patients, PTLD progression in vivo might be expected to cause progressively higher, or at least sustained, levels of IL-6 in the circulation. Several reasons may account for this not occurring. The adherent non-B cell population rather than the EBV-infected B cells appear to be the major contributors of IL-6 secretion in vitro by lymphoproliferative lesions. PTLD progression (10) * IL-6 content (U/ml) in initial culture supernatant after transfer to culture in vitro (day of culture in which the supernatant was obtained).
* Total number of days in culture during which IL-6 testing was performed. § Highest IL-6 level (U/ml) in culture supernatants (day of culture in which the supernatant was obtained). in vivo is thought to be due to uncontrolled growth and subsequent accumulation ofEBV-infected B cells (5, 6) . Endothelial cells and macrophages are present in PTLD tissue specimens because the tumor cells infiltrate vessels and may stimulate migration of reactive cells (22) . Thus, disease progression in vivo may not be accompanied by increased or sustained IL-6 production. Furthermore, IL-6 secretion by the lymphoproliferative lesions in vivo may not be reflected in the circulation due to inadequate tissue vascularization (23), local consumption, or degradation. Finally, the biological assay employed to measure IL-6 may underestimate the cytokine content in serum.
Recent work has demonstrated that IL-6 can exist in plasma/ serum in the form of 100-150-and 400-500-kD complexes that are not readily detectable in the B9 assay (24) . Thus, fluctuations in the IL-6 bioactivity content of PTLD sera may reflect changes in the state of IL-6 aggregation rather than its concentration.
Previous studies have demonstrated that IL-6 can act as a growth factor for EBV immortalized cells (8, 9) . These cells secrete IL-6 in the culture supernatant and utilize it as an autocrine growth factor (8) . When cultured under conditions that minimize endogenous IL-6 production, EBV-immortalized cells proliferate in response to exogenous IL-6 (9). In addition, retrovirus-mediated transduction of the IL-6 gene in EBV-immortalized human B cells rendered them tumorigenic in athymic mice, while the parental cells and those clones transduced with a control plasmid were generally nontumorigenic (10, 11 ). The mechanism ofIL-6 tumorigenicity in this experimental system appeared unrelated to a direct oncogenic effect of IL-6 on the EBV-immortalized cells. Rather, IL-6 at high concentrations appeared to inhibit profoundly cytotoxic functions of the splenocytes, and it was the further reduction of immunity that probably permitted tumor development ( 11) .
The results presented here demonstrate that patients with PTLD generally display abnormally high levels ofIL-6 bioactivity while the patients with uncomplicated courses posttrans- plant generally do not, and that PTLD lesions spontaneously produce high levels of IL-6 in vitro while inflammatory lymphoid tissues do not. In light ofthe experimental results linking IL-6 to increased tumorigenicity of EBV-immortalized cells, the present findings suggest that high level IL-6 production may be an important factor in the pathogenesis of PTLD.
The mechanism by which IL-6 may have a tumor-promoting effect in the context of posttransplant immunodeficiency was not addressed here. The cytokine could act directly on the target EBV-infected B cells and promote growth. However, B cells derived from PTLD tissues failed to grow less vigorously in vitro when removed from exposure to IL-6 produced at high levels by the adherent cells, suggesting that IL-6 may be indirectly tumorigenic. EBV positive lymphoproliferative disease rarely occurs in immunocompetent individuals but has been reported with variable frequencies in immunocompromised patients (5, 6) . In addition, PTLD can regress with improved immune function achieved by decreasing immunosuppressive medication (25) . Thus, host immunity plays an important role in the development and progression of PTLD. As IL-6 further inhibits immune effector functions in already immunodeficient hosts ( 11), a further reduction of immunity may represent the critical element in the pathogenesis of PTLD.
Previous studies evaluating the concentration of IL-6 in human body fluids, particularly serum, reported that patients with a variety of disease conditions display abnormally high levels of the cytokine, including infection with viruses and various bacteria (26-28), organ rejection after transplantation (29, 30) , rheumatoid arthritis (31) (32) (33) , and HIV infection (34, 35) . Patients with acute EBV-induced infectious mononucleosis do not generally display abnormally high levels of serum IL-6. In recent determinations only 3 of 18 patients with acute infectious mononucleosis were found to have abnormally high serum IL-6 levels (data not shown). There were, however, three posttransplant recipients without PTLD who developed either sepsis or organ rejection, and concomitantly displayed abnormally high serum IL-6 levels. These patients did not develop PTLD. While this raises questions as to the role ofIL-6 in the pathogenesis of PTLD, the precise site and mode of production in relation to the EBV-infected cells and immune effector cells may be critical in this patient population.
We have found evidence that the adherent cells are the source of much of the IL-6 bioactivity secreted in vitro by PTLD tissues. Due to their presence in limited numbers these adherent cells could not be fully phenotyped, except for their failure to express the B-cell specific marker CD20. They could be monocytes, endothelial cells, and/or fibroblasts, cell types known to produce large quantities ofIL-6 upon induction with a variety of stimuli, including lipopolysaccharide, IL-1, TNF, and other cytokines (7, 9, 36, 37) . Recent studies in AIDS patients have suggested that reactive macrophages and endothelial cells in high grade B cell lymphoma tissues express the IL-6 gene (38) . It will be important to identify the cellular source and the mechanisms responsible for IL-6 production within PTLD lesions. However, the information provided here may prove useful in the management of transplant recipients. De novo detection ofIL-6 at abnormally high levels in serum posttransplant should be considered as possibly predictive ofPTLD and, in the absence ofcontraindication, may suggest reduction of immunosuppressive therapy.
